JPS61134387A - Tocol derivative - Google Patents

Tocol derivative

Info

Publication number
JPS61134387A
JPS61134387A JP25412984A JP25412984A JPS61134387A JP S61134387 A JPS61134387 A JP S61134387A JP 25412984 A JP25412984 A JP 25412984A JP 25412984 A JP25412984 A JP 25412984A JP S61134387 A JPS61134387 A JP S61134387A
Authority
JP
Japan
Prior art keywords
compound
formula
parts
give
reacted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP25412984A
Other languages
Japanese (ja)
Inventor
Masahiro Takeuchi
武内 優広
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DIA TOPY NOUGEI KK
Original Assignee
DIA TOPY NOUGEI KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DIA TOPY NOUGEI KK filed Critical DIA TOPY NOUGEI KK
Priority to JP25412984A priority Critical patent/JPS61134387A/en
Publication of JPS61134387A publication Critical patent/JPS61134387A/en
Pending legal-status Critical Current

Links

Abstract

NEW MATERIAL:A compound shown by the formula I(R1-R4 are H, or lower alkyl; when R2 is CH2, R1 is not H). EXAMPLE:5, 7-Diethyl-8-methyltocol. USE:A promoting substance for normal cell division. Having improved effect and durability. PREPARATION:For example, an alpha-tocopherol shown by the formula II(R is group shown by the formula III) is reacted with chlorine under light irradiation, to give a chloromethylated derivative at the 5- and the 7-positions, which is reacted with Mg to give a compound shown by the formula IV. A carbonic acid gas is introduced into a reaction solution, which is reduced with LiAlH4, to give a hydroxyethylated derivative at the 5- and the 7-positions. The hydroxyl group at the 6-position is acetylated, and reacted with HBr, to give a compound shown by the formula V. this compound is reacted with Mg, a propyne gas is introduced to it, and the 6-position is deacetylated, to give a compound shown by the formula I(R1 is H; R2 and R3 are C2H5; R4 is CH3).

Description

【発明の詳細な説明】 「産業上の利用分野」 本発明は、動物、特に人間の細胞を組織培養、し、イン
ターフェロン等の薬剤を生産する際の正常細胞分裂促進
物質として有用な新規トコール誘導体に関するものであ
る。
Detailed Description of the Invention "Field of Industrial Application" The present invention provides novel tocol derivatives that are useful as normal cell division promoters when producing drugs such as interferon by tissue culturing animal, especially human, cells. It is related to.

「従来の技術」 従来インビトロで動物、特に人間の細胞を継代培養する
と、50代程度の分裂回数で増殖が停止することが知ら
れている。これは、染色体変異等がおこっているためで
あり、このことは検査により確認されている。一方50
代以降分裂増殖するものもあったが、こ、れらはある意
味では、腫瘍細胞に属するものである。
"Prior Art" Conventionally, it is known that when animal, especially human, cells are subcultured in vitro, proliferation stops after about 50 generations of cell division. This is due to chromosomal mutations, etc., and this has been confirmed by testing. On the other hand, 50
There were some cells that divided and proliferated after the first generation, but in a sense, these belong to tumor cells.

しかして、上記継代培養に於いて、ビタミンEを培養培
地に添加すると、正常細胞の分裂回数が2倍程度伸びる
ことが報告されている。このビタミンEの作用機構は完
全には解明されていないが、フリーラジカルの発生を抑
えるビタミンEの抗酸化作用が、増殖や分化に作用する
からであろうと考えられている。
However, it has been reported that when vitamin E is added to the culture medium during the above-mentioned subculture, the number of divisions of normal cells increases by about twice. Although the mechanism of action of vitamin E has not been completely elucidated, it is thought that the antioxidant effect of vitamin E, which suppresses the generation of free radicals, affects proliferation and differentiation.

そこで、ビタミンEと同じように抗酸化作用を看するク
ロマン誘導体を添加する多くの試みがなされたが、これ
らはいずれも正常細胞分裂促進作用を有しなかった。そ
れ故このような正常細胞分裂促進作用を示すものは、現
在迄は、ビタミンEしか知られていない。
Therefore, many attempts have been made to add chroman derivatives that have an antioxidant effect like vitamin E, but none of these had an effect of promoting normal cell division. Therefore, until now, only vitamin E is known to exhibit such a normal cell division promoting effect.

「発明が解決しようとする問題点」 前記したように、正常細胞の1代培養の代数を増加させ
る作用を有する物質としてはビタミンEしか知られてい
ないが、ビタミンEにしても、その正常細胞分裂促進効
力及び効力の長期的持続性等の点で実用上まだ十分に満
足すべきものではない。
"Problems to be Solved by the Invention" As mentioned above, vitamin E is the only substance known to have the effect of increasing the algebraic number of one-generation cultures of normal cells. In terms of mitogenic efficacy and long-term sustainability of efficacy, it is still not fully satisfactory for practical purposes.

「問題点を解決するための手段」 本発明者等は、この点に着目し、ビタミンE以外で正常
細胞促進作用を有する化合物を求めて、鋭意研究の結果
、下記式で表わされる新規化合物を人間等の培養培地に
添加すると、培養物の染色体変異を抑え、培養効率が下
がるのを防止し、しかもビタミンEと比べて代謝されに
くいので、その効力が長期的に持続することを見出し、
本発明□に到達した。
"Means for Solving the Problem" The present inventors focused on this point, searched for a compound other than vitamin E that has a normal cell promoting effect, and as a result of intensive research, discovered a new compound represented by the following formula. We have discovered that when added to the culture medium of humans, etc., it suppresses chromosomal mutations in the culture and prevents the culture efficiency from decreasing, and since it is less metabolized than vitamin E, its efficacy lasts for a long time.
The present invention □ has been achieved.

(式中、R1ないしR4は、水素原子または低級アルキ
ル基を衷わすが、R2がメチル基を表わす場合は、R□
は水J原子を表わさない、)本発明の新規化合物は1次
式で示す反応式に従って製造することが出来る0式中R
は1次式:化合物Bは、化合物Aに光照射下に塩素を導
入する公知の方法によって製造することが出来る。
(In the formula, R1 to R4 represent a hydrogen atom or a lower alkyl group, but when R2 represents a methyl group, R□
does not represent a water atom) The novel compound of the present invention can be produced according to the reaction formula shown in the linear formula.
is a linear formula: Compound B can be produced by a known method of introducing chlorine into Compound A under light irradiation.

この際次式: で表される塩素化物のような種々の塩素化物が副生する
ので、これらは薄層クロマトグラフィーで分画し、分離
すればよい、このようにして得られた化合物Bに、Mg
を添加し公知のグリニャル反応を行わせれば、化合物C
が得られる。
At this time, various chlorinated products such as those represented by the following formula are produced as by-products, so these can be fractionated and separated by thin layer chromatography. , Mg
is added and a known Grignard reaction is carried out, compound C
is obtained.

化合物Cに常法によって、炭酸ガスを導入し化合物りを
得、これをL iA L Ha、HCI及び水で還元す
れば、化合物Eが得られる。
Compound E is obtained by introducing carbon dioxide gas into Compound C in a conventional manner to obtain Compound E, which is then reduced with LiA L Ha, HCI, and water.

化合物Eをそれ自体周知の方法例えば、酢酸でエステル
化すれば化合物Fが得られる。その際次式: で表される化合物が副生ずるので、これを薄層クロマト
グラフィーによって分画、分岐して化合物Fを単離すれ
ばよい、この化合物FにHBrを加えて、5−17−位
のヒドロキシエチル基の水酸基を臭素化すると化合物G
が得られる。
Esterification of compound E by methods known per se, for example with acetic acid, gives compound F. At that time, a compound represented by the following formula is produced as a by-product, so compound F can be isolated by fractionating and branching this by thin layer chromatography. HBr is added to compound F to obtain 5-17- When the hydroxyl group of the hydroxyethyl group in position is brominated, compound G
is obtained.

化合物Gを常法によって脱ハロゲン化すれば化合物Hが
得られ、この化合物Hに水素添加すれば化合物Iが得ら
れ、ついで化合物Iを加水分解すると、化合物Jが得ら
れる。
Compound H is obtained by dehalogenating Compound G by a conventional method, Compound I is obtained by hydrogenating Compound H, and Compound J is obtained by hydrolyzing Compound I.

2、R□が低級アルキルを表わす場合、(A)    
                (K)化合物(A)
に、エチルリチウムを100℃什近の温度で反応させ、
反応終了後クロマト分画によって化合物(K)を単離す
る。
2. When R□ represents lower alkyl, (A)
(K) Compound (A)
, by reacting ethyllithium at a temperature of around 100°C,
After the reaction is completed, compound (K) is isolated by chromatographic fractionation.

上記反応l、2に於いては、R2、R3、R4がメチル
基の場合について例示したが、これらが水素原子及び低
級アルキル基を表す場合にも、同様にして製造すること
が出来る。
In the above Reactions 1 and 2, the case where R2, R3, and R4 are methyl groups was exemplified, but it can be produced in the same manner even when these represent a hydrogen atom or a lower alkyl group.

「実施例」 次に実施例を示し本発明を更に説明するが、本発明はこ
れら実施例に限定されない0例中、数量を表わす部は重
量部である。
"Examples" Next, the present invention will be further explained with reference to Examples, but the present invention is not limited to these Examples. In 0 Examples, the parts representing the quantities are parts by weight.

実施例1 化合物(A)(α−トコフェロール)100部をクロロ
ホルム1000部に溶解し、これに紫外線照射下で、塩
素400部を導入し、約250℃で2時間反応させる。
Example 1 100 parts of compound (A) (α-tocopherol) is dissolved in 1000 parts of chloroform, 400 parts of chlorine is introduced into the solution under ultraviolet irradiation, and the mixture is reacted at about 250° C. for 2 hours.

尽応終了後、目的物をクロマト分画により単離して、化
合物(B)10部を得る。
After completion of the reaction, the target product is isolated by chromatographic fractionation to obtain 10 parts of compound (B).

化合物(B)100部を無水エーテル2000部に溶解
し、これにMg300部を加える。約100℃で2時間
反応させて、化合物(C)を生成させる。この反応液に
二酸化炭素ガスを、159℃でtsoo部導入し1反応
終了後常法により化合物(D)30部を11離する。
100 parts of compound (B) is dissolved in 2000 parts of anhydrous ether, and 300 parts of Mg is added thereto. Compound (C) is produced by reacting at about 100° C. for 2 hours. Two parts of carbon dioxide gas is introduced into this reaction solution at 159°C, and after one reaction is completed, 30 parts of compound (D) are separated by 11 parts by a conventional method.

化合物(D)100部を無水エーテル3000部に溶解
させ、これにL iA I H4400部を加え、次い
で35%塩酸100fiと水3000部とを加えて、i
so℃で2時間反応させる0反応終了後常法により中離
して化合物(E)90部を得た。
100 parts of compound (D) was dissolved in 3000 parts of anhydrous ether, 4400 parts of LiA I H was added thereto, 100 fi of 35% hydrochloric acid and 3000 parts of water were added, and i
After the reaction was completed for 2 hours at SO° C., 90 parts of Compound (E) was obtained by neutralization using a conventional method.

化合物(E)100部をエーテル3000部に溶解し、
これに酢酸400部を加えて、100℃で4時間エステ
ル化反応させる0反応終了液から薄層クロマト分画によ
り化合物(F)60部を単離した。化合物(F)10(
)部なベンゼン3000部に溶解し、これに35%HB
r400部を加え、100℃で5時間反応させて化合物
CG)を生成させる。ついでこの反応液にMg300部
を加え、100℃で2時間反応させる0反応終了後常法
により単離すれば化合物(H)90部が得られる、化合
物Hを単離することなく、上記反応液中にプロピンガス
3000部倉、100℃で導入し、脱ハロゲ、ン化して
化合物(I)90部を得る、化合物(I)100部に2
規定KOH50部、エーテル1000部及び水2000
部を加えて。
Dissolve 100 parts of compound (E) in 3000 parts of ether,
400 parts of acetic acid was added to this, and esterification reaction was carried out at 100° C. for 4 hours. 60 parts of compound (F) was isolated from the reaction completed liquid by thin layer chromatography fractionation. Compound (F) 10 (
) in 3,000 parts of benzene, and add 35% HB to this.
Add 400 parts of r and react at 100° C. for 5 hours to produce compound CG). Next, 300 parts of Mg is added to this reaction solution, and the reaction is allowed to proceed at 100°C for 2 hours. After completion of the reaction, 90 parts of compound (H) can be obtained by isolation using a conventional method. 3,000 parts of propyne gas was introduced into the tank at 100°C, and 90 parts of compound (I) was obtained by dehalogenation and oxidation.
Standard KOH 50 parts, ether 1000 parts and water 2000 parts
Add part.

150℃で2時間加水分解する。常法により後処理して
、淡黄色粘稠油状の化合物J(5,7−ジエチル−8−
メチルトコール)90部を得た。生成物は、抗酸化作用
を有し、脂肪族の溶媒に良く溶解し、296mpに吸収
極大を有する。b−p、202〜212℃ 実施例2 塩素の使用量を1 /’ 2とする以外は、実施例1と
同様にして5−位のメチル基だけがクロル化した化合物
B′を製造した。同様に実施・例1に準じて、5.7−
ジエチル−8−メチルトコールを淡黄色粘稠油状物質と
して得た。生成物は、抗酸化作用を有し、脂肪族の溶媒
に良く溶解・し、297℃終に吸収極大を有する。b、
p、200〜21O℃ 参考例 Eagleの基本培地に、10%の子牛の血清とオーレ
オマイシン50 m g / lと次表に記載の添加物
質100mg/見を加え、ヒト正常繊維芽細胞を培養し
た。培養代数と細胞変異の有無を測定し、結果を次表に
示した。尚、培養代数の表示は、最大正常細胞蔚代培養
代数によった。
Hydrolyze at 150°C for 2 hours. Compound J (5,7-diethyl-8-
90 parts of methyl tocol were obtained. The product has an antioxidant effect, is well soluble in aliphatic solvents, and has an absorption maximum at 296 mp. b-p, 202-212°C Example 2 Compound B' in which only the methyl group at the 5-position was chlorinated was produced in the same manner as in Example 1, except that the amount of chlorine used was 1/'2. Similarly, according to Example 1, 5.7-
Diethyl-8-methyltocol was obtained as a pale yellow viscous oil. The product has an antioxidant effect, is well soluble in aliphatic solvents, and has an absorption maximum at 297°C. b,
p, 200-210°C Reference Example: To Eagle's basic medium, add 10% calf serum, 50 mg/l of aureomycin, and 100 mg/l of the additives listed in the table below, and culture human normal fibroblasts. Cultured. The culture algebra and the presence or absence of cell mutations were measured, and the results are shown in the table below. The culture number is expressed based on the maximum normal cell culture number.

表 上記結果から明らかなように、本発明の化合物は、ビタ
ミンEよりも正常細胞継代培養代数を伸ばすのに、はる
かに効果がある。
As is clear from the results in the table above, the compounds of the present invention are much more effective than vitamin E in increasing the number of passages of normal cells.

「作用」 培養後のビタミンE等の添加物の残量を検査したところ
、無添加はtmsr/見、化合物A添加は10mg/J
L本発明化合物J添加はz3mg/見残存していた。こ
れより、本発明化合物は、代謝分解が遅いことがわかる
。このことは、本発明化合物が効力の持続性に優れてい
ることを示すものであると共に、これが培養代数を伸ば
す効果に優れている原因であると推測される。
"Effect" When we tested the remaining amount of additives such as vitamin E after culturing, it was tmsr/J without additives, and 10 mg/J with compound A added.
When the compound of the present invention J was added, 3 mg/ml remained. This shows that the compound of the present invention undergoes slow metabolic decomposition. This indicates that the compound of the present invention has excellent persistence of efficacy, and it is also presumed that this is the reason why it is excellent in the effect of extending the culture algebra.

「発明の効果」 以上述べたように、本発明の新規化合物は、ビタミンE
と比較して、培養代数を伸ばす効果に優れ、しかもその
効果の持続性も長いという効果を有するので、インター
フェロン等の薬剤が効率的に生産される等、斯業に貢献
するところ極めて大きい、またこれらのことから、本発
明の化合物は、老化の防止にも優れた効果を示すことが
期待される。
"Effects of the Invention" As stated above, the novel compound of the present invention has vitamin E
Compared to other methods, it has an excellent effect on extending the culture algebra and has a long-lasting effect, so it will contribute greatly to this industry, such as by efficiently producing drugs such as interferon. From these facts, the compound of the present invention is expected to exhibit excellent effects in preventing aging.

Claims (1)

【特許請求の範囲】[Claims] (1)次式: ▲数式、化学式、表等があります▼ (式中、R_1ないしR_4は、水素原子または低級ア
ルキル基を表わすが、R_2がメチル基を表わす場合は
、R_1は水素原子を表わさない。)で表わされるトコ
ール誘導体。
(1) The following formula: ▲There are mathematical formulas, chemical formulas, tables, etc.▼ (In the formula, R_1 to R_4 represent a hydrogen atom or a lower alkyl group, but if R_2 represents a methyl group, R_1 represents a hydrogen atom. Tocol derivatives represented by
JP25412984A 1984-12-03 1984-12-03 Tocol derivative Pending JPS61134387A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP25412984A JPS61134387A (en) 1984-12-03 1984-12-03 Tocol derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP25412984A JPS61134387A (en) 1984-12-03 1984-12-03 Tocol derivative

Publications (1)

Publication Number Publication Date
JPS61134387A true JPS61134387A (en) 1986-06-21

Family

ID=17260623

Family Applications (1)

Application Number Title Priority Date Filing Date
JP25412984A Pending JPS61134387A (en) 1984-12-03 1984-12-03 Tocol derivative

Country Status (1)

Country Link
JP (1) JPS61134387A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674876A (en) * 1995-01-20 1997-10-07 Research Development Foundation ρ-heteroatom-substituted phenols and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHROMANS AND TOCOPHEROLS *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674876A (en) * 1995-01-20 1997-10-07 Research Development Foundation ρ-heteroatom-substituted phenols and uses thereof

Similar Documents

Publication Publication Date Title
US20080014249A1 (en) Compositions and therapeutic methods involving isoflavones and analogues thereof
US3780102A (en) Substituted cinnamamides
JPS62174094A (en) Alpha, alpha-trehalose derivative and production thereof
NL7905630A (en) IMIDA SOLE DERIVATIVES.
US2870151A (en) Mqrpholine -ethers
EP0272478B1 (en) Glycyrrhetic acid derivatives and use thereof
CA1201127A (en) Biphenylylpropionic acid derivative, process for preparing the same and pharmaceutical composition containing the same
US2870150A (en) Morpholine ethers
US2554533A (en) Bromo-trichloro butenyl acetate
JPS61134387A (en) Tocol derivative
GB1436513A (en) Expoxidation process
IL67049A (en) P-(alkyl or alkenyl)-benzene or phenol derivatives,process for their preparation and pharmaceutical compositions containing them
CN113429412B (en) Analgesic and its preparation method and use
EP0013818A1 (en) Organosilicon compounds, their preparation and anti-tumor agents containing the same
EP0046242B1 (en) Anti-tumor agent comprising an organosilicon compound
US7084133B2 (en) Dicarba-closo-dodecaborane derivatives
US2757210A (en) Coupling of conjugated olefins and alcohols by hydroxyl free-radicals
US3449418A (en) Etherified bisaryl compounds
JPS6026154B2 (en) Production method of basic oxazine dye
US2878254A (en) N, n'-alkylene-bis-(3-hydroxypiperidine) compounds and preparation thereof
JPS59222415A (en) Immune adjusting agent
US4767872A (en) Epoxide derivatives
US3641146A (en) Halocolchicine derivatives
US3076015A (en) Preparation of [2-cyano-3-alkoxy (or hydroxy)] thio-2-alke)namides
CN114874135B (en) Small molecular compound for resisting breast cancer and preparation method thereof